 NEW YORK, July 1, 2021 PRNewswire -- Immunic, Inc. Nasdaq: IMUX, a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced U.S. Food and Drug Administration FDA clearance of its Investigational New Drug IND application for the phase 3 ENSURE program of lead asset IMU-838, the companys selective oral DHODH inhibitor, in patients with relapsing-remitting multiple sclerosis RRMS. In addition, the FDA also cleared the companys separate IND application for the supportive phase 2 CALLIPER trial of IMU-838 in patients with progressive multiple sclerosis PMS. 